Pharmacovigilance in India, Uganda and South Africa with reference to WHO’s minimum requirements

International Journal of Health Policy and Management

Volumn 4, Issue 5, 2015, Pages 295-305

  Maigetter, Karen ^a,b   Pollock, Allyson M ^c   Kadam, Abhay ^d   Ward, Kim ^e   Weiss, Mitchell G ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Foundation for Research in Community Health India   (India)

^e UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

Adverse drug reaction (ADR); India; Pharmacovigilance (PV); South Africa; Uganda

Indexed keywords

COMPARATIVE STUDY; DEVELOPING COUNTRY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HEALTH CARE POLICY; HUMAN; INDIA; SOUTH AFRICA; STANDARDS; UGANDA; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; DRUG MONITORING; HEALTH POLICY; HUMANS; INDIA; PHARMACOVIGILANCE; SOUTH AFRICA; UGANDA; WORLD HEALTH ORGANIZATION;

EID: 85002441950     PISSN: None     EISSN: 23225939     Source Type: Journal    
DOI: 10.15171/ijhpm.2015.55     Document Type: Article

References (26)

1. World Health Organization (WHO). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: WHO; 2002.
2. Lalvani P, Milstein J. Access to New Health Products in Low Income Countries and the Challenge of Pharmacovigilance. [cited 16 Feb 2013]. Available from: http://pdpaccess.org/downloads/projects/full-papers/Pharmacovigilance%20 Discussion%20Paper.pdf
3. World Health Organization (WHO). The Safety of Medicines in Public Health Programmes: Pharmacovigilance an Essential Tool. Geneva: WHO; 2006.
4. Ghosh AK. Current problems and future aspects of pharmacovigilance in India. Int J Pharm Bio Sci 2011; 2: 15-9.
5. Vaidya SS, Bpharm JJ, Heaton PC, Steinbach M. Overview and comparison of postmarketing drug safety surveillance in selected developing and well-developed countries. Drug Inf J 2010; 44: 519-33. doi: 10.1177/009286151004400501
6. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle- income countries: a questionnaire-based analysis. Drug Saf 2010; 33: 689-703. doi: 10.2165/11536390-000000000-00000
7. World Health Organization (WHO). Minimum Requirements for a Functional Pharmacovigilance System. [cited12 Aug 2013]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/PV_Minimum_Requirements_2010_2.pdf
8. World Health Organization (WHO). Pharmacovigilance Toolkit, version 2.0, 24 January 2012. [cited 25 Apr 2013]. Available from: http://apps.who.int/medicinedocs/en/d/Js19107en
9. WHO Uppsala Monitoring Centre (UMC). The WHO Programme [internet]. [cited 25 Apr 2013]. Available from: http://www.who-umc.org
10. Strengthening Pharmaceutical Systems (SPS) Program. Safety of Medicines in Sub-Saharan Africa: Assessment of Pharmacovigilance Systems and their Performance. Arlington, VA: Management Sciences for Health; 2011.
11. Central Drugs Standard Control Organization (CDSCO). Schedule Y (amended version) Drugs and Cosmetic Rules. [cited 8 Aug 2013]. Available from:http://cdsco.nic.in/html/schedule-y%20%28amended%20version-2005%29%20original. htm
12. Central Drugs Standard Control Organization (CDSCO). Pharmacovigilance Programme of India (PvPI) for Assuring Drug Safety. Government of India; 2013.
13. Gupta YK. Pharmacovigilance Programme for India [internet]. 2010. [cited 8 Aug 2013]. Available from: http://pharmabiz.com/NewsDetails.aspx?aid=57406&sid=9
14. Bandekar MS, Anwikar SR, Kshirsagar NA. Quality check of spontaneous adverse drug reaction reporting forms of different countries. Pharmacoepidemiol Drug Saf 2010; 19: 1181-5. doi: 10.1002/pds.2004
15. Adithan C, Dkhar SA. Drug Alert Regional Pharmacovigilance Center. Drug Alert 2012; 6: 2-3.
16. Subhashini DK. Proactive pharmacovigilance vital for drug safety [internet]. [cited 7 Aug 2013]. Available from: http://saffron.pharmabiz.com/article/detnews.asp?articleid=53054&se ctionid=50
17. Central Drugs Standard Control Organization (CDSCO). Four Years’ Achievements 2009-2013. [cited 30 Aug 2013]. Available from: http://cdsco.nic.in/writereaddata/Four%20years%20 achievements%20of%20CDSCO%20(2009-2013).pdf
18. Ndagije HB. What is Current Practice of Pharmacovigilance in Uganda? [cited 18 Apr 2013]. Available from: http://africapv2012. files.wordpress.com/2012/04/day-2_5_country-presentations-nras_h-ngadije-uganda-compatibility-mode.pdf
19. Ndagije HB. Working together with the Public Health Programmes: a regulator’s perspective for addressing the minimum requirements for Pharmacovigilance. [cited 13 Aug 2013]. Available from: http://www.nda.or.ug
20. National Drug Authority Uganda. Structure of NDA/Departments/Drug Information. [cited 26 Apr 2013]. Available from: http://www. nda.or.ug/
21. United Nations Statistics Division. UNdata Uganda. [cited 20 Aug 2013]. Available from: http://data.un.org/Search.aspx?q=uganda
22. Medicines Control Council SA. Medicines and Related Substances Control Act 101 of 1965 after Amendment by the Medicines and Related Substances Control Amendment Act (Act 90 of 1097) Regulations 34 and 37; 1997.
23. Uppsala Monitoring Center (UMC) VigiBase. Numbers of Reports per year in South Africa between 2002 and 2012. Uppsala: Uppsala Monitoring Center; 2013.
24. United Nations Statistics Division. UN data South Africa. [cited 20 Aug 2013]. Available from: http://data.un.org/Search. aspx?q=south+africa
25. South Africa Government. Census 2011 Statistical release -P0301.4/Statistics South Africa. [cited 15 Aug 2013]. Available from: http://www.statssa.gov.za
26. Systems for Improved Access to Pharmaceutical Services (SIAPS). Pharmacovigilance Systems in Five Asian Countries. Arlington, VA: Management Sciences for Health: 2013.